Oesophageal Cancer Clinical Trial
Official title:
Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge™) for Post Chemo-radiotherapy Surveillance in Patients With Oesophageal Cancer -a Feasibility Study.
This is a feasibility study testing the use of the Cytosponge™ device in patients with known oesophageal cancer treated with pre-operative or definitive chemoradiation. All participants will receive one Cytosponge™ procedure at one time-point within 4-16 weeks after completion of chemoradiotherapy.
In this feasibility study, we are investigating a novel way to test for remaining or reoccurring oesophageal cancer following chemoradiotherapy. The technique used to test this is called a Cytosponge™. We will be testing the use of the Cytosponge™ to determine completion rate, safety and acceptability of the procedure. Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet. The Cytosponge™ will be processed for evidence of residual cancer through analysis of cellular atypia and molecular biomarkers. Where available, the results will be compared with histology. Up to fifty patients will be recruited to the trial across 11 sites. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05685862 -
Laser Speckle Contrast Imaging, Surgical Eye & ICG Fluorescence Imaging for Perfusion Assessment of the Gastric Conduit
|
||
| Recruiting |
NCT01795768 -
Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
|
Phase 2 | |
| Completed |
NCT05266300 -
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
|
||
| Recruiting |
NCT03978377 -
Cardiopulmonary Toxicity of Thoracic Radiotherapy
|
||
| Active, not recruiting |
NCT03653052 -
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
|
Phase 2 | |
| Recruiting |
NCT05489250 -
The PLATON Network
|
||
| Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
| Terminated |
NCT01795976 -
NY-ESO-1 T Cells in OG Cancer
|
Phase 2 | |
| Recruiting |
NCT01843829 -
A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer
|
Phase 2 | |
| Completed |
NCT01915693 -
ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study
|
Phase 3 | |
| Completed |
NCT02382237 -
Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition
|
N/A | |
| Recruiting |
NCT04517448 -
Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
|
||
| Recruiting |
NCT04232735 -
Evidence Based Information Provision to Improve Decision Making After Oesophagogastric Cancer Diagnosis (SOURCE)
|
N/A | |
| Recruiting |
NCT05642819 -
REVOLUTION Surgery (REVOLUTION Surgery)
|
||
| Recruiting |
NCT04001478 -
Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
|
||
| Recruiting |
NCT02741856 -
Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05600608 -
Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome
|
N/A | |
| Recruiting |
NCT04481256 -
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
|
N/A | |
| Recruiting |
NCT05057013 -
HMBD-001 in Advanced HER3 Positive Solid Tumours
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06046846 -
Prehabilitation Via a Mobile Application in Oesophago-gastric Cancer
|
N/A |